In this study, SLC1A5 inhibition not only enhanced the anti-tumor effect of Almonertinib on EGFR mutant cell lines (H1975), but greatly improved the anti-tumor effect of Almonertinib on EGFR WT cell lines (A549). Here, EGFR is linked to neoplasm.